NYSE - Delayed Quote • USD
Pfizer Inc. (PFE)
At close: May 17 at 4:01 PM EDT
After hours: 8:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 15 | 15 | 19 | 19 |
Avg. Estimate | 0.45 | 0.55 | 2.35 | 2.74 |
Low Estimate | 0.3 | 0.41 | 2.15 | 2.45 |
High Estimate | 0.59 | 0.67 | 2.63 | 3.13 |
Year Ago EPS | 0.67 | -0.17 | 1.84 | 2.35 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 13 | 12 | 18 | 18 |
Avg. Estimate | 13.05B | 14.89B | 60.61B | 62.93B |
Low Estimate | 12.05B | 13.35B | 58.21B | 60.86B |
High Estimate | 13.99B | 16.02B | 62.26B | 64.5B |
Year Ago Sales | 12.73B | 13.23B | 58.5B | 60.61B |
Sales Growth (year/est) | 2.50% | 12.50% | 3.60% | 3.80% |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | 0.57 | -0.34 | -0.22 | 0.52 |
EPS Actual | 0.67 | -0.17 | 0.1 | 0.82 |
Difference | 0.1 | 0.17 | 0.32 | 0.3 |
Surprise % | 17.50% | 50.00% | 145.50% | 57.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.45 | 0.55 | 2.35 | 2.74 |
7 Days Ago | 0.45 | 0.55 | 2.36 | 2.76 |
30 Days Ago | 0.42 | 0.56 | 2.08 | 2.56 |
60 Days Ago | 0.45 | 0.58 | 2.2 | 2.74 |
90 Days Ago | 0.45 | 0.58 | 2.2 | 2.72 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | 2 | -- |
Up Last 30 Days | 6 | 3 | 18 | 9 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
CURRENCY IN USD | PFE | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -32.80% | -- | -- | 8.00% |
Next Qtr. | 423.50% | -- | -- | 12.40% |
Current Year | 27.70% | -- | -- | 5.60% |
Next Year | 16.60% | -- | -- | 13.00% |
Next 5 Years (per annum) | -1.33% | -- | -- | 11.14% |
Past 5 Years (per annum) | -1.53% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 5/2/2024 |
Reiterates | BMO Capital: Outperform to Outperform | 5/2/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
Related Tickers
BMY Bristol-Myers Squibb Company
44.03
-0.18%
JNJ Johnson & Johnson
154.64
+0.23%
MRK Merck & Co., Inc.
131.19
+0.24%
ABBV AbbVie Inc.
166.42
+1.26%
LLY Eli Lilly and Company
770.00
-0.15%
GILD Gilead Sciences, Inc.
67.72
-0.21%
AMGN Amgen Inc.
312.47
-0.71%
GSK GSK plc
44.98
+0.22%
AZN AstraZeneca PLC
76.90
-0.18%
SNY Sanofi
48.67
-0.31%